In contrast, 50 nmoles of capsazepine, which effectively abolished the response to the highest doses of other cannabinoids, did not show an effect on WIN 55,212-2 (p = 0.7619; Figure 5A), confirming this synthetic cannabinoid as a reference for CB1R/CB2R-mediated antinociception in the diabetic neuropathy model used here. The gene discussed is CNR1; the disease is diabetic neuropathy.